Celerity is excited to offer deeper, more adaptable, and more accessible sequencing power to our collaboration partners than ever before.

Announcing TruSight™ Oncology 500 for tumor mutational burden assessment

  • The VENTANA pan-TRK (EPR17341) Assay[1] is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types

  • The assay is expected to provide improved data on the prevalence of TRK proteins in tumor tissue studies

  • The significance of TRK fusion proteins is currently being investigated in various cancer indications

Roche launches first IVD pan-TRK immunohistochemistry assay

With over 70 pathologist and nearly 130 laboratory assistants communication and effective operation within Celerity's Network of Laboratories is critical. Former laboratory directors and educators Paul Bachner and David Wilkinson share the lessons they’ve learned over nearly a century of combined experience.

A Masterclass in Leadership

How can newly minted – or veteran – laboratory directors rise to their full potential?

Meet the Celerity team at AACR 2019.

Friday, March 29-Wednesday, April 3, 2019
Georgia World Congress Center
Atlanta, Georgia

AACR Annual Meeting 2019

services@celeritybio.com

Tel: (303)-531-1667

300 Center Drive

Suite G-310

Superior, CO 80027